Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Otsuka | History Defined

The Difference the New ADHD Drug Named Simtriyo Makes and How It Works in the Brain

The FDA approved SIMTRIYO for ADHD in adults and children, offering a new three-neurotransmitter treatment while carrying important safety warnings.

Simtriyo Will Be a Federally Controlled Substance, and Its DEA Schedule Will Shape How Easily Families Can Get It

Simtriyo Will Be a Federally Controlled Substance, and Its DEA Schedule Will Shape How Easily Families Can Get It

Simtriyo cannot be filled until the DEA assigns a controlled substance schedule. What that means for access, timing, and two boxed warnings.

The New ADHD Drug Carries Two Boxed Warnings and Will Be a Controlled Substance

The New ADHD Drug Carries Two Boxed Warnings and Will Be a Controlled Substance

The new ADHD drug Simtriyo carries two boxed warnings, pediatric suicidality monitoring, and CNS stimulant status pending DEA scheduling.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Approves Centanafadine for ADHD: Who Qualifies, How It Differs, and What Side Effects Appeared

FDA-approved centanafadine, a first-in-class non-stimulant for ADHD in adults and children 6 and up over 20 kg. What families should know.

FDA Set to Decide on a New Non-Stimulant ADHD Drug for Children and Adults on July 24

FDA decides on centanafadine July 24, 2026 — a first-in-class non-stimulant ADHD drug for children, adolescents, and adults. Four Phase 3 trials support the application.

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why Akebia Therapeutics Stock Is Soaring After Hours

Why Akebia Therapeutics Stock Is Soaring After Hours

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical.

Why Are Akebia Therapeutics Shares Falling Today?

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.…

Five Companies Developing Second Generation Psychedelics For Mental Health

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Compass Pathways

Field Trip Health

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,044 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play